Like other malignancies, prostate tumors are thought to contain cancer stem-like cells (CSCs) that are responsible for growth, metastasis, and therapy resistance. ΔNp63 (also called p40) is a regulator of normal prostate stem/progenitor cell activities and a marker of normal basal epithelial cells. The levels of ΔNp63 are reduced in prostate adenocarcinomas, although there is also evidence that ΔNp63 is involved in CSC regulation and drives metastasis to the bone. We studied metastatic deposits of prostate cancers with isoform-specific ΔNp63 and TAp63 antibodies. We identified p63-positive cells in only 3 of 42 metastatic prostate tumors (7%), including 2/38 (5.3%) "usual-type" adenocarcinomas. ΔNp63 and TAp63 isoforms were present in the nuclei of a small subpopulation (< 1%) of tumor cells in these metastases. ΔNp63-positive cells showed a basal-like cell phenotype (cytokeratin 8- and androgen receptor-negative, high molecular weight cytokeratin- and cytokeratin 19-positive), distinct from the tumor bulk. TAp63-positive cells were similar but were sometimes cytokeratin 8-positive. A subset of ΔNp63-positive tumor cells were CD44-positive, a marker of "basal" CSCs but were not positive for the "epithelial" CSC marker ALDH1. TAp63 was not associated with either of these CSC markers. None of the tumors containing p63-positive cells showed evidence of bone metastasis, compared with 28% of the p63-negative tumors. These data show that both ΔNp63 and TAp63 are present in only a small proportion of prostate adenocarcinomas and do not associate with metastasis. The data suggest heterogeneity of CSCs in prostate cancer, similar to other cancer types.

Research Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Zluty kopec 7 656 53 Brno Czech Republic

Zobrazit více v PubMed

Shen MM, Rubin MA (2019) Prostate cancer research at the crossroads. Cold Spring Harb Perspect Med 9:a036277. https://doi.org/10.1101/cshperspect.a036277 PubMed DOI

Wang G, Zhao D, Spring DJ, DePinho RA (2018) Genetics and biology of prostate cancer. Genes Dev 32:1105–1140. https://doi.org/10.1101/gad.315739.118 PubMed DOI PMC

Li JJ, Shen MM (2019) Prostate stem cells and cancer stem cells. Cold Spring Harb Perspect Med 9:a030395. https://doi.org/10.1101/cshperspect.a030395 PubMed DOI

Ali HR, Dawson S-J, Blows FM, Provenzano E, Pharoah PD, Caldas C (2011) Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance. Breast Cancer Res 13:R118. https://doi.org/10.1186/bcr3061 PubMed DOI PMC

Liu Y, Nenutil R, Appleyard MV, Boylan M, Thompson AM, Coates PJ (2014) Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer 110:2063–2071. https://doi.org/10.1038/bjc.2014.105 PubMed DOI PMC

Hsu C-L, Chung F-H, Chen C-H, Hsu TT, Liu SM, Chung DS, Hsu YF, Chen CL, Ma N, Lee HC (2016) Genotypes of cancer stem cells characterized by epithelial-to-mesenchymal transition and proliferation related functions. Sci Rep 6:32523. https://doi.org/10.1038/srep32523 PubMed DOI PMC

Sampayo RG, Bissell MJ (2019) Cancer stem cells in breast and prostate: fact or fiction? Adv Cancer Res 144:315–341. https://doi.org/10.1016/bs.acr.2019.03.010 PubMed DOI PMC

Crum CP, McKeon FD (2010) p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 5:349–371. https://doi.org/10.1146/annurev-pathol-121808-102117 PubMed DOI

Nekulova M, Holcakova J, Coates P, Vojtesek B (2011) The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett 16:296–327. https://doi.org/10.2478/s11658-011-0009-9 PubMed DOI PMC

Orzol P, Holcakova J, Nekulova M, Nenutil R, Vojtesek B, Coates PJ (2015) The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histol Histopathol 30:503–521. https://doi.org/10.14670/HH-30.503 PubMed DOI

Melino G, Memmi EM, Pelicci PG, Bernassola F (2015) Maintaining epithelial stemness with p63. Sci Sig 8:re9. https://doi.org/10.1126/scisignal.aaa1033 DOI

Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775. https://doi.org/10.1016/S0002-9440(10)64814-6 PubMed DOI PMC

Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M (2005) p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A 102:11355–11360. https://doi.org/10.1073/pnas.0500165102 PubMed DOI PMC

Pignon J-C, Grisanzio C, Geng Y, Song J, Shivdasani R, Signoretti S (2013) p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci U S A 110:8105–8110. https://doi.org/10.1073/pnas.1221216110 PubMed DOI PMC

Huang Y, Hamana T, Liu J, Wang C, An L, You P, Chang JYF, Xu J, McKeehan WL, Wang F (2015) Prostate sphere-forming stem cells are derived from the P63-expressing basal compartment. J Biol Chem 290:17745–17752. https://doi.org/10.1074/jbc.M115.661033 PubMed DOI PMC

Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON (2010) Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 70:491–501. https://doi.org/10.1002/pros.21083 PubMed DOI

Portillo-Lara R, Alvarez MM (2015) Enrichment of the cancer stem phenotype in sphere cultures of prostate cancer cell lines occurs through activation of developmental pathways mediated by the transcriptional regulator ΔNp63α. PLoS One 10:e0130118. https://doi.org/10.1371/journal.pone.0130118 PubMed DOI PMC

Nylander K, Vojtesek B, Nenutil R, Lindgren B, Roos G, Zhanxiang W, Sjöström B, Dahlqvist Å, Coates PJ (2002) Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 198:417–427. https://doi.org/10.1002/path.1231 PubMed DOI

Sailer V, Stephan C, Wernert N, Perner S, Jung K, Kristiansen G (2013) Comparison of p40 (ΔNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells? Histopathology 63:50–56. https://doi.org/10.1111/his.12116 PubMed DOI

Shah RB, Kunju LP, Shen R, LeBlanc M, Zhou M, Rubin MA (2004) Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol 122:517–523. https://doi.org/10.1309/WRM5-1C70-P1NB-FE4K PubMed DOI

Ali TZ, Epstein JI (2008) False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol 32:1890–1895. https://doi.org/10.1097/PAS.0b013e31817ce994 PubMed DOI

Osunkoya AO, Hansel DE, Sun X, Neto GJ, Epstein JI (2008) Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am J Surg Pathol 32:461–467. https://doi.org/10.1097/PAS.0b013e318157020e PubMed DOI

Wu A, Kunju LP (2013) Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics. Arch Pathol Lab Med 137:1179–1184. https://doi.org/10.5858/arpa.2013-0254-CR PubMed DOI

Tan H-L, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, de Marzo AM, Epstein JI, Lotan TL (2015) Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol 28:446–456. https://doi.org/10.1038/modpathol.2014.115 PubMed DOI

Uchida K, Ross H, Lotan T, Pignon J-C, Signoretti S, Epstein JI, Illei PB (2015) ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Hum Pathol 46:384–389. https://doi.org/10.1016/j.humpath.2014.11.011 PubMed DOI

Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, de Marzo AM, Lotan TL (2018) ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. Prostate 78:896–904. https://doi.org/10.1002/pros.23646 PubMed DOI PMC

Rosenbluth JM, Johnson K, Tang L, Triplett, Pientenpol JA (2009) Evaluation of p63 and p73 antibodies for cross-reactivity. Cell Cycle 8:3702–3706. https://doi.org/10.4161/cc.8.22.10036 PubMed DOI

Nekulova M, Holcakova J, Nenutil R, Stratmann R, Bouchalova P, Müller P, Mouková L, Coates PJ, Vojtesek B (2013) Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Arch 463:415–425. https://doi.org/10.1007/s00428-013-1459-4 PubMed DOI

Lee AHS (2013) Use of immunohistochemistry in the diagnosis of problematic breast lesions. J Clin Pathol 66:471–477. https://doi.org/10.1136/jclinpath-2012-201109 PubMed DOI

Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Brandao DF, Chahud F, Zucoloto S (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47:458–466. https://doi.org/10.1111/j.1365-2559.2005.02249.x PubMed DOI

Liu Y, Nekulova M, Nenutil R, Horakova I, Appleyard MV, Murray K, Holcakova J, Galoczova M, Quinlan P, Jordan LB, Purdie CA, Vojtesek B, Thompson AM, Coates PJ (2020) ∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem-like cells in human ER+ and HER2+ breast cancers. J Pathol Clin Res 6:83–93. https://doi.org/10.1002/cjp2.149 PubMed DOI

Kim J, Villadsen R, Sørlie T et al (2012) Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci U S A 109:6124–6129. https://doi.org/10.1073/pnas.1203203109 PubMed DOI PMC

Maitland NJ, Collins AT (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26:2862–2870. https://doi.org/10.1200/JCO.2007.15.1472 PubMed DOI

Parsons JK, Gage WR, Nelson WG, De Marzo AM (2001) p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 58:619–624. https://doi.org/10.1016/s0090-4295(01)01311-5 PubMed DOI

Resetkova E, Reis-Filho JS, Jain RK, Mehta R, Thorat MA, Nakshatri H, Badve S (2010) Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 123:97–108. https://doi.org/10.1007/s10549-009-0619-3 PubMed DOI

Epstein JI, Egevad L, Humphrey PA, Montroni R (2014) Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e6–e19. https://doi.org/10.1097/PAS.0000000000000238 PubMed DOI

Reiner T, de Las PA, Parrondo R, Perez-Stable C (2007) Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice. Mol Cancer Res 5:1171–1179. https://doi.org/10.1158/1541-7786.MCR-07-0024 PubMed DOI

Di Giacomo V, Tian TV, Mas A et al (2017) ΔNp63α promotes adhesion of metastatic prostate cancer cells to the bone through regulation of CD82. Oncogene 36:4381–4392. https://doi.org/10.1038/onc.2017.42 PubMed DOI PMC

Gu G, Yuan J, Wills M, Kasper S (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67:4807–4815. https://doi.org/10.1158/0008-5472.CAN-06-4608 PubMed DOI

Kurita T, Medina RT, Mills AA, Cunha GR (2004) Role of p63 and basal cells in the prostate. Development 131:4955–4964. https://doi.org/10.1242/dev.01384 PubMed DOI

Tucci P, Agostini M, Grespi F, Markert EK, Terrinoni A, Vousden KH, Muller PAJ, Dötsch V, Kehrloesser S, Sayan BS, Giaccone G, Lowe SW, Takahashi N, Vandenabeele P, Knight RA, Levine AJ, Melino G (2012) Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A 109:15312–15317. https://doi.org/10.1073/pnas.1110977109 PubMed DOI PMC

Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR (2001) Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 49:271–278. https://doi.org/10.1177/002215540104900214 PubMed DOI

Wang Y, Hayward S, Cao M, Thayer K, Cunha G (2001) Cell differentiation lineage in the prostate. Differentiation 68:270–279 DOI

Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D’Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2:78–91. https://doi.org/10.1016/j.stemcr.2013.11.009 PubMed DOI

Coates PJ, Nenutil R, Holcakova J, Nekulova M, Podhorec J, Svoboda M, Vojtesek B (2018) p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. Virchows Arch 472:351–359. https://doi.org/10.1007/s00428-018-2324-2 PubMed DOI

Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer

DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma